Scientific evidence suggests, but does not prove, that eating 1.5 ounces of most nuts, such as almonds, as part of a diet low in saturated fat and cholesterol may reduce the risk of heart disease
Oral VK2735 (Viking Therapeutics) -- Phase 2# VK2735 is unique as the only dual GLP-1/GIP agonist with an oral formulation in clinical development: 12.2% weight loss at 13 weeks (oral tablet) 97% of treatment groups achieved at least 5% weight loss Oral Phase 3 expected Q3 2026 The injectable SC formulation achieved 14.7% at 13 weeks Oral Amycretin (Novo Nordisk) -- Phase 1# Novo Nordisk's oral amycretin demonstrated 13.1% weight loss at just 12 weeks, the highest early-stage oral result
Perovic, D., et al
The Mistaken Identity: Why Harmless Pollen Triggers Chaos When you inhale pollen, your immune system has to make a split-second decision: friend or foe
Results A total of 11 studies were included in this meta-analysis, including 6 studies on GLP-1 RA, 1 study on GLP-1 and GIP dual receptor agonists, 1 study on orlistat, 2 studies on phentermine-topiramate, and 1 study on naltrexone-bupropion (Additional file 1: Table S2) [22,23,24,25,26,27,28,29,30,31,32]
